Highest-materiality recent filing
McKesson Q4 adj EPS $11.69 (+16% YoY); FY2027 guidance $43.80-$44.60
Q4 revenue $96.3B (+6%), full-year $403.4B (+12%); GAAP EPS $13.71, adjusted EPS $39.11 (+18% FY).
McKesson enters $5B revolving credit facility maturing April 2031
New $5.0B revolving credit facility replaces $1.0B 364-day and $4.0B five-year facilities.
McKesson unit enters $2B senior secured credit facility with term loans and revolver
$750M term loan A-1 due 2031, $250M term loan A-2 due 2028, and $1B revolver due 2031.
McKesson reaffirms FY2026 outlook, sets Q4 earnings release for May 7, 2026
Q4 fiscal 2026 earnings to be released after market close on May 7, 2026; webcast at 4:30 PM ET.
McKesson CFO Britt Vitalone to retire; Kenny Cheung named successor effective May 29, 2026
Britt Vitalone retires as CFO effective May 28, 2026; will advise as contractor from July 2 at $50K/month.
McKesson Q3 revenue $106.2B +11%, adj EPS $9.34 +16%, raises FY guidance
GAAP EPS $9.59 vs $6.95 YoY; adjusted EPS $9.34 vs $8.03, up 16%.
McKesson Q2 adjusted EPS $9.86, +39% YoY; revenue record $103.2B; raises FY26 guidance
Quarterly revenue $103.2B (+10% YoY); GAAP EPS $8.92 vs $1.87; adjusted EPS $9.86 vs $7.07 (+39%).
Fiscal 2026 Adjusted EPS guidance raised and narrowed to $38.05-$38.55 from $37.10-$37.90.
McKesson reorganizes into 4 segments; restates FY2025 revenue of $359B under new structure
Starting Q2 FY2026, McKesson will report 4 segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, Medical-Surgical Solutions.
Consolidated revenue $97.8B, up 23% YoY; GAAP diluted EPS $6.25 (down $0.75); Adjusted EPS $8.26 (up 5%).
McKesson shareholders elect all 12 director nominees; ratify auditor; approve say-on-pay
All 12 board nominees elected; Maria N. Martinez received most votes against (6.1M of ~100M cast).
McKesson raises FY2026 adjusted EPS guidance to $36.90-$37.70 from $36.75-$37.55
Adjusted EPS guide increased by $0.15 at midpoint to $36.90-$37.70.
McKesson issues $2B notes to fund acquisition of 70% stake in Community Oncology Revitalization
Issued $650M 4.650% notes due 2030, $650M 4.950% notes due 2032, $700M 5.250% notes due 2035.
Q4 consolidated revenues $90.8B (+19% YoY); GAAP diluted EPS $10.01; adjusted diluted EPS $10.12 (+64%).
McKesson Q3 FY25 revenue $95.3B (+18%); raises adjusted EPS guidance to $32.55-$32.95
Q3 FY25 revenue $95.3B (+18% YoY); GAAP EPS $6.95 (+57%); adjusted EPS $8.03 (+4%).
GAAP diluted EPS $6.95 vs $4.42 prior year; adjusted EPS $8.03 vs $7.74 (+4%).
McKesson Q2 FY2025 revenue $93.7B (+21%), adj. EPS $7.07 (+13%), raises FY25 adj. EPS guidance
Revenue $93.7B, +21% YoY; GAAP diluted EPS $1.87 (down 62% vs $4.92); adjusted EPS $7.07 (+13%).
McKesson issues $500M 4.250% notes due 2029 to redeem higher-rate 2026 notes
Issued $500M aggregate principal of 4.250% Notes due 2029 at 99.946% of par.
McKesson reaffirms FY2025 adj. EPS $31.75-$32.55, Q2 range $6.70-$7.00
Reaffirmed fiscal 2025 full-year adjusted EPS guidance $31.75-$32.55.
McKesson signs deal to buy 70% of Core Ventures (FCS) for ~$2.49B cash
Purchase price approx. $2.49B in cash for ~70% controlling equity interest in Core Ventures (FCS's admin services org).
McKesson Q1 adjusted EPS $7.88 (+8% YoY); raises FY2025 guidance, boosts dividend 15%
Revenues $79.3B (+6% YoY); net income $915M (-4%); GAAP EPS $7.00 flat.
McKesson shareholders elect all 11 directors, ratify auditor at 2024 annual meeting
All 11 board nominees elected by majority; Brian S. Tyler received 103.4M for, 0.8M against.
McKesson elects Deborah Dunsire to board; two directors to step down at 2024 annual meeting
Deborah Dunsire, former CEO of H. Lundbeck, elected to McKesson board effective June 3, 2024; will serve on Compensation/Talent and Finance committees.
McKesson Q4 revenue +11% but adjusted EPS -14%; FY2025 guidance 14-17% growth
Q4 revenue $76.4B (+11% YoY); full-year revenue $309B (+12% YoY).
McKesson FQ3 revenue $80.9B (+15% YoY), adjusted EPS $7.74 (+12%), raises FY guidance
Revenue $80.9B up 15% YoY; GAAP EPS from continuing ops $4.42 vs $7.65 (down 42%).
Linda Mantia and Susan R. Salka will not be standing for re-election at the Corporation’s 2024 annual meeting of shareholders (“Annual Meeting”), and their terms will expire effective at the Annual Meeting.
On May 31, 2024, the Board of Directors (“Board”) of McKesson Corporation (“Corporation”) elected Deborah Dunsire, M.D. as a director of the Corporation and appointed her to the Board’s Compensation and Talent Committee and Finance Committee, effective June 3, 2024.
Linda Mantia and Susan R. Salka will not be standing for re-election at the Corporation’s 2024 annual meeting of shareholders (“Annual Meeting”), and their terms will expire effective at the Annual Meeting.
Max materiality 0.90 · Median 0.70 · Most common event earnings